LGALS3BP
Galectin-3-binding protein
Also known as: 90K, BTBD17B, CyCAP, gp90, LG3BP_HUMAN, M2BP, MAC-2-BP, TANGO10B
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q08380
- Gene
- LGALS3BP
- Ensembl
- ENSG00000108679
- Chromosome
- 17
- Canonical length
- 585 aa
- Protein class
- Cancer-related genes, Plasma proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
- Quaternary structure
- Homodimer
OverviewNCBI Gene
The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. LGALS3BP has been found elevated in the serum of patients with cancer and in those infected by the human immunodeficiency virus (HIV). It appears to be implicated in immune response associated with natural killer (NK) and lymphokine-activated killer (LAK) cell cytotoxicity. Using fluorescence in situ hybridization the full length 90K cDNA has been localized to chromosome 17q25. The native protein binds specifically to a human macrophage-associated lectin known as Mac-2 and also binds galectin 1. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
585 residues, UniProt reviewed canonical sequence.
>Q08380|LGALS3BP
1 MTPPRLFWVW LLVAGTQGVN DGDMRLADGG ATNQGRVEIF YRGQWGTVCD NLWDLTDASV
61 VCRALGFENA TQALGRAAFG QGSGPIMLDE VQCTGTEASL ADCKSLGWLK SNCRHERDAG
121 VVCTNETRST HTLDLSRELS EALGQIFDSQ RGCDLSISVN VQGEDALGFC GHTVILTANL
181 EAQALWKEPG SNVTMSVDAE CVPMVRDLLR YFYSRRIDIT LSSVKCFHKL ASAYGARQLQ
241 GYCASLFAIL LPQDPSFQMP LDLYAYAVAT GDALLEKLCL QFLAWNFEAL TQAEAWPSVP
301 TDLLQLLLPR SDLAVPSELA LLKAVDTWSW GERASHEEVE GLVEKIRFPM MLPEELFELQ
361 FNLSLYWSHE ALFQKKTLQA LEFHTVPFQL LARYKGLNLT EDTYKPRIYT SPTWSAFVTD
421 SSWSARKSQL VYQSRRGPLV KYSSDYFQAP SDYRYYPYQS FQTPQHPSFL FQDKRVSWSL
481 VYLPTIQSCW NYGFSCSSDE LPVLGLTKSG GSDRTIAYEN KALMLCEGLF VADVTDFEGW
541 KAAIPSALDT NSSKSTSSFP CPAGHFNGFR TVIRPFYLTN SSGVDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against LGALS3BP can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.29
- Highest tissue expression
- 470 nTPM
Expression across tissuesHPA
Tissue
- salivary gland: 470 nTPM
- choroid plexus: 328 nTPM
- heart muscle: 309 nTPM
- stomach: 298 nTPM
- duodenum: 295 nTPM
- adrenal gland: 264 nTPM
Single-cell type
- decidual stromal cells: 897 nCPM
- enterocytes: 863 nCPM
- extravillous trophoblasts: 553 nCPM
- colonocytes: 510 nCPM
- foveolar cells: 491 nCPM
- enteric transient amplifying cells: 331 nCPM
Immune cell
- naive CD4 T-cell: 69 nTPM
- memory CD4 T-cell: 43 nTPM
- naive CD8 T-cell: 33 nTPM
- intermediate monocyte: 27 nTPM
- T-reg: 26 nTPM
- total PBMC: 25 nTPM
Brain region
- choroid plexus: 315 nTPM
- white matter: 293 nTPM
- medulla oblongata: 292 nTPM
- spinal cord: 198 nTPM
- pons: 188 nTPM
- cerebellum: 179 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about LGALS3BP.
Disease | ImmuneIEDB
Conditions an epitope on LGALS3BP was assayed in.
- colon cancer T cell
- skin melanoma T cell
ReferencesPubMed · IEDB
Publications for LGALS3BP from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Circulating autoantibodies to LGALS3BP: a novel biomarker for cancer.
2013 · Dis Markers · RCR 0.2 · 7 citations - The specificity of nephritogenic antibodies. V. Glomerular localization of anti-GP 330 and anti-GP 90 antibodies present in passive Heymann serum.
1988 · Br J Exp Pathol · RCR 0.1 · 3 citations
Reference: T cellIEDB
2 publications
- Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.
2013 · Cell Mol Immunol · RCR 0.4 · 14 citations - Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
2022 · Front Immunol · RCR 0.2 · 3 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.43
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.08
- DepMap mean gene effect
- -0.17
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of LGALS3BP in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LGALS3BP as an antibody target. Whether an autoantibody or antibody against LGALS3BP could matter depends on whether native LGALS3BP is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LGALS3BP is annotated as secreted, so native LGALS3BP circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label LGALS3BP as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...